MDNA Life Sciences Inc. (MDLS)

MDNA Life Sciences Income Statement

Financials in millions USD. Fiscal year is October - September.

Year Ending	TTM	Sep 30, 2021	Sep 30, 2020
Revenue	3.6	3.6	0.11
Revenue Growth (YoY)	-	3298.10%	-
Cost of Revenue	1.82	1.82	0.11
Gross Profit	1.78	1.78	-0
Selling, General & Admin	2.08	2.08	1.67
Research & Development	0.72	0.72	1.52
Operating Expenses	2.8	2.8	3.19
Operating Income	-1.02	-1.02	-3.19
Interest Expense / Income	1.67	1.67	1.41
Other Expense / Income	0.31	0.31	-0.03
Pretax Income	-3.79	-3.79	-5.29
Net Income	-3	-3	-4.57
Preferred Dividends	0.79	0.79	0.73
Net Income Common	-3.79	-3.79	-5.29
Free Cash Flow	-0.62	-0.62	-1.63
Gross Margin	49.49%	49.49%	-0.19%
Operating Margin	-28.29%	-28.29%	-3009.37%
Profit Margin	-105.14%	-105.14%	-4994.05%
Free Cash Flow Margin	-17.25%	-17.25%	-1536.33%
EBITDA	-1.48	-1.48	-3.3
EBITDA Margin	-41.11%	-41.11%	-3114.02%
Depreciation & Amortization	0.64	0.64	0.58
EBIT	-2.12	-2.12	-3.88
EBIT Margin	-58.86%	-58.86%	-3664.34%

Source: IPO financials are sourced from S-1 and S-1/A filings submitted to the Securities and Exchange Commission (SEC).